Appointment of Dr Esra Ogru as Executive Director Research & Development

The Board of Directors is pleased to announce the appointment of Dr Esra Ogru as an Executive Director of the Company in charge of Research & Development.

Dr Ogru is Phosphagenics’ Vice-President of Research and Development and is responsible for the coordination and management of the pre-clinical and clinical research in Australia and internationally. She achieves this through leadership of a team of experienced biochemists and organic chemists and strategic collaborations.

In this role, Dr Ogru has developed commercial opportunities for both the Company’s nutraceutical division and pharmaceutical technologies, such as transdermal drug delivery and drug enhancement platforms for cancer, heart disease and chronic pain management.

Dr Ogru works with Phosphagenics’ Scientific Advisory Board, in maintaining and enhancing the level of scientific rigor across the company’s operations. The Scientific Advisory Board comprises internationally respected scientists from the University of Bern, Tufts University (USA), the University of California (Davis) in Sacramento and Monash University.

Prior to joining Phosphagenics in 2001, Dr Ogru conducted research at Monash University’s Department of Biochemistry and Molecular Biology for Metabolic Pharmaceuticals Limited. As a senior member of the obesity and diabetes research group, she was involved in the management and coordination of the pre-clinical and clinical development of anti-obesity peptides.

Dr Ogru holds a Bachelor of Science (Hons) and a PhD in Biochemistry & Molecular Biology from Monash University in Melbourne. She is experienced in many aspects of academic and commercial research and development and has published in peer journals.

For further information, please contact Dr Esra Ogru, Phosphagenics Limited on +61 3 9605 5900 or 0402 080 846.

Attached for release to the market is an Appendix 3X Notice on behalf of Dr Ogru.